Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × ALK+ Advanced NSCLC × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 233 Carcinoma, Non-Small-Cell Lung 196 Prostatic Neoplasms 107 Neoplasms 91 Multiple Myeloma 77 Colorectal Neoplasms 65 Neoplasm Metastasis 64 Parkinson Disease 4, Autosomal Dominant Lewy Body 61 Lung Neoplasms 61 Ovarian Neoplasms 50 Leukemia, Myeloid, Acute 48 Melanoma 47 Carcinoma, Renal Cell 41 Carcinoma, Hepatocellular 41 Stomach Neoplasms 39 Squamous Cell Carcinoma of Head and Neck 37 Brain Neoplasms 37 Triple Negative Breast Neoplasms 36 Recurrence 36 Leukemia, Lymphocytic, Chronic, B-Cell 36 Urinary Bladder Neoplasms 34 Lymphoma, Follicular 34 Myasthenia Gravis 33 Colonic Neoplasms 33 Head and Neck Neoplasms 31 Small Cell Lung Carcinoma 28 Rectal Neoplasms 28 Pancreatic Neoplasms 28 Nasopharyngeal Carcinoma 28 Lymphoma, Non-Hodgkin 26

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡